Mineralys Therapeutics, Inc. Profile Avatar - Palmy Investing

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administ…

Biotechnology
US, Radnor [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Mineralys Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Mineralys Therapeutics, Inc. can't present revenue by segment

End of MLYS's Analysis
CIK: 1933414 CUSIP: 603170101 ISIN: US6031701013 LEI: - UEI: -
Secondary Listings
MLYS has no secondary listings inside our databases.